EATG » EMA/FDA

EMA/FDA

Odefsey approved in Europe

European Commission grants marketing authorization for Gilead’s single tablet regimen Odefsey® (emtricitabine, rilpivirine, tenofovir alafenamide) for the treatment of HIV Odefsey is the second single tablet regimen containing the Descovy…

CHMP adopts positive opinion for generic atazanavir

On 23 June 2016 the Committee for Medicinal Products for Human Use (CHMP), the scientific committee of the European Medicines Agency (EMA), adopted a positive opinion, recommending the granting of a…

Brexit spells upheaval for EU and UK drug regulation

Britain's vote to leave the European Union spells regulatory uncertainty for drug companies, with the London-based European Medicines Agency (EMA), which approves treatments for all EU countries, expected to have…

EMA and FDA reinforce collaboration on patient engagement

New working group established to exchange best practices The European Medicines Agency (EMA) and the United States Food and Drug Administration (FDA) have set up a new ‘cluster’ on patient…

EMA Management Board: highlights of June 2016 meeting

New civil society representatives join the Board; EMA multiannual work plan to 2020 and overarching stakeholder relations management framework adopted New civil society representatives join the Board At its June…

1 15 16 17